Elicio reports complete responses in pancreatic cancer
Elicio Therapeutics (NASDAQ:ELTX) announced promising clinical observations regarding its lead immunotherapy candidate, ELI-002 7P, in the treatment of metastatic mKRAS pancreatic ductal adenocarcinoma (PDAC).





-640x360.webp&w=3840&q=75)




